Back to School: How biopharma can reboot drug development. Access exclusive analysis here

APD125: Preliminary Phase II data

In a double-blind, U.S. Phase II trial in 173 chronic insomnia patients, 10 and 40 mg doses of oral APD125 reduced WASO from baseline

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE